Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

Resource Type

CF Research News

Authors

MW Konstan, DR VanDevanter, SM Rowe, M Wilschanski, E Kerem, I Sermet-Gaudelus, E DiMango, P Melotti, J McIntosh, K De Boeck on behalf of the ACT CF Study Group

References

J Cyst Fibros. 2020 Jul;19(4):595-601. doi: 10.1016/j.jcf.2020.01.007. Epub 2020 Jan 23.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

Ataluren [3]
Clinical trial [4]

Date

Tuesday, July 14, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [5]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/efficacy-and-safety-ataluren-patients-nonsense-mutation-cystic

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-20-00013_FINAL_Konstan_030920.pdf [2] https://pubmed.ncbi.nlm.nih.gov/31983658/ [3] https://www.ecfs.eu/research-article-keywords/ataluren [4] https://www.ecfs.eu/research-article-keywords/clinical-trial [5] https://www.ecfs.eu/resource-guideline-type/other-guidelines